The study, published in Gut, shows that patients with hepatitis B surface antigen (HBsAg) levels below 100 IU/mL face an annual hepatocellular carcinoma (HCC) risk of only 0.08%, comparable to the general population. The findings come from two of the world’s largest HBV cohorts, ERADICATE-B and REVEAL-HBV, with more than 2,600 inactive CHB patients followed for over 25 years. Notably, about one-third (37%) of inactive CHB patients had HBsAg <100 IU/mL, meaning that millions worldwide may fall into this ultra-low-risk category. “HBsAg <100 IU/mL identifies patients with what we call a ‘partial cure’ of hepatitis B,” said Doctor Tai-Chung Tseng, lead author. Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold.